Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 6/20 | 0.54 |
| ▸ | CA2 | P00918 | 6/20 | 0.54 |
| ▸ | CA9 | Q16790 | 6/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1208976 | 1.00 | PYGB (0.62) | PYGBGAACA1CA2CA9 | |
| SCHEMBL1208980 | 1.00 | PYGB (0.62) | PYGBGAACA1CA2CA9 | |
| SCHEMBL28491648 | 0.98 | PYGB (0.65) | PYGBGAACA1CA2CA9 | |
| SCHEMBL10939188 | 0.98 | PYGB (0.65) | PYGBGAACA1CA2CA9 | |
| SCHEMBL4816502 | 0.98 | PYGB (0.65) | PYGBGAACA1CA2CA9 | |
| SCHEMBL13563944 | 0.84 | PYGB (0.45) | PYGBGAACA1CA2CA9 | |
| SCHEMBL13564576 | 0.84 | PYGB (0.45) | PYGBGAACA1CA2CA9 | |
| SCHEMBL29977113 | 0.83 | CA12 (0.57) | PYGBGAACA1CA2CA9 | |
| SCHEMBL30498599 | 0.83 | CA12 (0.57) | PYGBGAACA1CA2CA9 | |
| SCHEMBL30957909 | 0.82 | PYGB (0.69) | PYGBGAACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512486-B2 | BLUE POWDER AND USE THEREOF IN COSMETICS | OREAL (FR) | 2023-07-12 | — | — | EP | disclosed |
| WO-2021191830-A1 | METHODS AND REAGENTS FOR SYNTHESIZING NUCLEOSIDES AND ANALOGUES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2021-09-30 | — | — | WO | disclosed |
| EP-3512486-B1 | BLUE POWDER AND USE THEREOF IN COSMETICS | OREAL (FR) | 2020-10-21 | — | — | EP | disclosed |
| US-20200216430-A1 | CATALYST-FREE AND REDOX-NEUTRAL INNATE TRIFLUOROMETHYLATION AND ALKYLATION OF (HETERO)AROMATICS ENABLED BY LIGHT | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216430-A1 | CATALYST-FREE AND REDOX-NEUTRAL INNATE TRIFLUOROMETHYLATION AND ALKYLATION OF (HETERO)AROMATICS ENABLED BY LIGHT | CYBB, NOX4, NOX3 | PYGB 4744/4885GAA 2035/4885CA1 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.